Acadian Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$404K Buy
3,228
+174
+6% +$21.8K ﹤0.01% 1182
2025
Q1
$337K Buy
3,054
+383
+14% +$42.3K ﹤0.01% 1157
2024
Q4
$364K Sell
2,671
-16,321
-86% -$2.22M ﹤0.01% 1147
2024
Q3
$2.18M Buy
18,992
+14,828
+356% +$1.71M 0.01% 721
2024
Q2
$571K Buy
4,164
+698
+20% +$95.7K ﹤0.01% 1155
2024
Q1
$478K Sell
3,466
-27,778
-89% -$3.83M ﹤0.01% 1018
2023
Q4
$4.11M Sell
31,244
-15,528
-33% -$2.04M 0.02% 504
2023
Q3
$5.26M Buy
46,772
+22,741
+95% +$2.56M 0.02% 426
2023
Q2
$2.26M Sell
24,031
-83,629
-78% -$7.87M 0.01% 666
2023
Q1
$10.9M Buy
107,660
+54,311
+102% +$5.49M 0.05% 300
2022
Q4
$6.36M Buy
53,349
+20,253
+61% +$2.41M 0.03% 385
2022
Q3
$3.51M Buy
+33,096
New +$3.51M 0.02% 498
2022
Q2
Sell
-293
Closed -$27K 1801
2022
Q1
$27K Buy
+293
New +$27K ﹤0.01% 1534
2021
Q3
Sell
-1,547
Closed -$151K 1913
2021
Q2
$151K Sell
1,547
-3,051
-66% -$298K ﹤0.01% 1520
2021
Q1
$447K Buy
4,598
+3,618
+369% +$352K ﹤0.01% 1240
2020
Q4
$94K Sell
980
-10,240
-91% -$982K ﹤0.01% 1770
2020
Q3
$1.08M Buy
11,220
+3,305
+42% +$318K ﹤0.01% 880
2020
Q2
$964K Buy
7,915
+6,787
+602% +$827K ﹤0.01% 976
2020
Q1
$98K Buy
1,128
+683
+153% +$59.3K ﹤0.01% 1353
2019
Q4
$48K Buy
+445
New +$48K ﹤0.01% 1605
2019
Q2
Sell
-91
Closed -$8K 1966
2019
Q1
$8K Sell
91
-370
-80% -$32.5K ﹤0.01% 1875
2018
Q4
$32K Buy
+461
New +$32K ﹤0.01% 1491
2018
Q1
Sell
-99
Closed -$8K 1779
2017
Q4
$8K Buy
+99
New +$8K ﹤0.01% 1443
2015
Q3
Sell
-177
Closed -$8K 1386
2015
Q2
$8K Buy
+177
New +$8K ﹤0.01% 1212